At the "Cell Design Innovation Forum 2022" held by the Tokyo Institute of Technology Open Innovation Organization on October 10, 17 (Monday), FRONTEO Neurolinguistics Research Institute Life Science AI Research and Development Department Research Team Manager Minoru Miyamoto will be on stage. We will give a lecture on the theme of "Drug discovery support system created by synergy of AI drug discovery and PLOM-CON analysis method".

 

■ Cell Design Innovation Forum 2022
Main event：Tokyo Institute of Technology Open Innovation Organization
Day and time: October 2022, 10 (Monday) 17:14-00:16
Venue: Online (pre-registration required)
Entry fee:free
URL : https://www.oi-p.titech.ac.jp/news/CellBasedDesignInnovation_2022.html
Program :

14:00 Opening

14:00-14:05 Opening Remarks Yoichi Oshima (Deputy Director/Professor, Open Innovation Organization, Tokyo Institute of Technology)

[Session 1] The “Cell Design Base” concept and the new “value of cells” that it aims for

14:05-14:35 Concept of "cell design center" and covariation network analysis technology to support it
Masayuki Murata (Specially Appointed Professor, Institute of Innovative Research, Tokyo Institute of Technology)

14:35-14:55 Problems of immune cell therapy using T cell lines and cell design aiming at improvement
Akihiko Yoshimura (Professor, Keio University School of Medicine)

14:55-15:15 Cell design for cultured meat
Masaharu Takeuchi (Professor, Graduate School of Information Science and Technology, The University of Tokyo)

15:15-15:35 Cell design that accelerates drug discovery and diagnostics: disease using spatiotemporal tissue analysis What can be achieved by optimal coupling of biomarker identification method and PLOM-CON analysis method
Junya Fujimoto (Associate Professor, The University of Texas MD Anderson Cancer Center)

15: 35-15: 40 Break

[Session 2] Social Implementation Strategy of “Cell Design Center” - Cell Design Value Chain

15:40-15:55 "Reseal cell technology", a cell-side tool that supports "cell design"
Masayuki Murata (Sercute Therapeutics Inc., Technical Advisor)

15:55-16:10 Drug discovery support system created by synergy between AI drug discovery and PLOM-CON analysis method
Minoru Miyamoto (FRONTEO Inc. Neurolinguistics Research Institute, Life Science AI R&D Department, Research Team, Director)

16:10-16:25 New drug discovery strategy created by antibody drug, resealed cell technology, and PLOM-CON analysis method
Tadashi Matsuura (Director/CTO, Perseus Proteomics Inc.)

16:25-16:40 The role of open innovation organizations to support the "cell design center"
Yoichi Oshima (Deputy Director/Professor, Open Innovation Organization, Tokyo Institute of Technology)

16:25-16:40 Summary
Osamu Watanabe (Executive Vice President (Research), Tokyo Institute of Technology Director, Open Innovation Organization)